BioSpace News Archive

Debbie’s Dream Foundation: Curing Stomach Cancer will host its Virtual Stomach Cancer Educational Symposium on Wednesday, February 9, 2022, from 9:00 a.m. to 5:00 p.m. EST.

AbbVie (NYSE: ABBV) will present further analyses on HUMIRA® (adalimumab) and the investigational uses of risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO), to be held February 16-19.

NEOGEN Corporation (NASDAQ: NEOG) announced today that it has added a new chemiluminescent substrate as part of the trusted K-Blue® product line.

Neuvivo today announced the publication of a paper on its lead candidate drug NP001 for the treatment of ALS in the peer-reviewed journal Muscle & Nerve.

Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased to provide an update on the patient recruitment for the phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz® photodynamic therapy (Ameluz®-PDT) in combination with the BF-RhodoLED® lamp in the U.S.

Building on over ten years of experience in the cell culture and isolation of cell products, KromaTiD is excited to announce the launch of a comprehensive suite of Cell and Blood Culture growth, isolation, processing, and quality control services.

ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Cabenuva.

Shineco, Inc., a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant.

The fourth calendar quarter of 2021 financial results demonstrate Utah Medical Products, Inc.’s continuing performance improvement despite many challenges related to the corona virus pandemic including on-again/off-again restrictions on so-called nonessential medical procedures, supply chain disruption, high inflation on raw materials, freight and labor costs as well as a continued shortage of labor and higher employee turnover.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointment of Nicholas Jackson, Ph.D., as President of Global Research and Development.